|
KMID : 1034820220180020243
|
|
Molecular & Cellular Toxicology
2022 Volume.18 No. 2 p.243 ~ p.251
|
|
|
Jageum-Jung, the herbal pharmaceuticals, inhibits the hepatic fibrogenesis as mediated with TGF-β1/smad signaling
|
|
Song Yu-Rim
Jang Mi-Hee
Jang Bo-Yun
Bae Su-Jin
Bak Seon-Been
Lee Sung-Min
Yun Un-Jung
Lee Ju-Hee
Park Sang-Mi
Jung Dae-Hwa
Sa Bok-Suk
Song Jong-Kuk
Lee Eun-Hye
Kim Kwang-Youn
Park Kwang-Il
Kim Young-Woo
Kim Sang-Chan
|
|
|
Abstract
|
|
|
Background: Herbal prescriptions have various effects and their efficacy is potentiated by the use of combinations of medicinal herbs.
Objective: Jageum-Jung (JGJ) is a traditional oriental medical prescription composed of five herbs. It has been used for detoxification, and as an anti-inflammatory and antitumor agent. However, the effect of JGJ on hepatic fibrogenesis is unclear.
Results: We investigated the role of JGJ in TGF-β1/smad signaling, which is implicated in fibrogenesis, and its hepatoprotective effect in CCl4-treated mice with liver fibrosis. Treatment of LX-2 cells with TGF-β induced expression of mediators (α-SMA, PAI-1, and MMP-2) of fibrogenesis and activation of proinflammatory cytokines (TNF-α, IL-1β, and IL-6). However, these were downregulated by pretreatment with JGJ. In mice, oral administration of JGJ prevented liver injury induced by CCl4, as indicated by decreases in the ALT and AST levels.
Conclusions: JGJ inhibits hepatic fibrogenesis and TGF-β1/Smad signaling.
|
|
|
KEYWORD
|
|
|
Herbal pharmaceutical, Jageum-Jung, Liver fibrosis, TGF-β1/smad
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|